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Bone resorptionted that after an acute stroke, intravenous zoledronate prevented bone loss in the
hemiplegic hip. Participants from the trial also volunteered for trans-iliac bone biopsy, to assess the early
effects of stroke and zoledronate on iliac bone remodelling.
Methods: Patients with acute stroke were randomly assigned to a single intravenous dose of zoledronate 4 mg
or placebo within 5 weeks of stroke. Biopsies from 14 patients (3 female, 11 male, mean age 71±11) were
suitable for analysis. These were taken at mean 10 weeks (±2) post-stroke, and included 5 patients who had
received zoledronate. Histomorphometry was performed on undecalciﬁed sections using light and
ﬂuorescence microscopy. Static and dynamic indices of remodelling were compared to a local reference
range from healthy controls. Osteoclasts and their precursors were identiﬁed on frozen sections using
tartrate resistant acid phosphatase (TRAP) staining. Dual-energy x-ray absorptiometry (DXA) of the proximal
femora was performed at baseline and 6 months later.
Results: The eroded surface in cancellous bone (ES/BS) was signiﬁcantly higher in stroke patients than
controls (5.7% vs. ref 1.6%, pb0.0001). Although ES/BS did not differ between zoledronate and placebo-
treated groups, there were signiﬁcantly fewer osteoclasts and their precursors in zoledronate-treated
individuals (p=0.023). Bone formation indices (osteoid surface, OS/BS and mineralising surface, MS/BS) were
signiﬁcantly lower in stroke patients than controls and although OS/BS was higher in the zoledronate group
than the placebo group (p=0.033), MS/BS was not different (p=0.924). There were no differences between
hemiplegic and unaffected sides for any histomorphometric parameter despite asymmetric reductions in hip
bone mineral density (p=0.013).
Conclusion: Stroke patients had higher resorption indices and lower bone forming surfaces than controls,
consistent with uncoupling of bone remodelling. These ﬁndings are preliminary and a larger study is
required to evaluate the contributions of gender, age and hemiplegic status to the remodelling imbalance.
Zoledronate therapy was associated with a reduction in osteoclastic cell numbers consistent with its known
mode of action in bone.
© 2009 Elsevier Inc.Open access under CC BY-NC-ND license.IntroductionWe previously demonstrated that a single intravenous infusion of
zoledronate given within 5 weeks of acute stroke protected against
the deleterious effects of hemiplegia on hip bone mineral density [1].
After a stroke, there is a reduction in bone mineral density in the
hemiplegic hip as assessed by DXA. Despite the magnitude androject grant from the National
g from the arthritis research
al Research Council (Training
Cambridge NIHR Biomedical
udy design; in the collection,
e report; nor in the decision to
-NC-ND license.rapidity of these effects, the underlyingmechanisms at the bone tissue
level in stroke patients are unexplained. Biochemical bone marker
studies have suggested an increase in bone resorption and reduced
bone formation in the ﬁrst week after stroke compared to controls [2],
which persisted throughout the ﬁrst year [3,4]. Although bone density
reduction following stroke is site speciﬁc (with the greatest losses at
sites such as the affected hip [5]), more generalised bone loss as a
result of bed-rest and alterations in calciotropic hormone regulation is
also described [6]. Year-long treatment with daily oral risedronate
after acute stroke was associated with suppression of bone resorption
markers, but also an unexpected increase in bone formation markers
[4]. Bone formation might be suppressed after stroke due to a
combination of reduced PTH and reduced active vitamin D [7], the
result of raised ionised calcium inhibiting the parathyroid gland [8].
The aims of this study were three-fold: to assess indices of cancellous,
endocortical and cortical bone turnover in the iliac bone 10 weeks
630 K.E.S. Poole et al. / Bone 44 (2009) 629–633following stroke; to evaluate the early effects of zoledronate on bone
remodelling; and to compare histomorphometric parameters in
patients with stroke to a UK healthy reference range. Secondary
aims were to investigate the relative contributions of the side of
biopsy (hemiplegic or contra-lateral), baseline 25 hydroxyvitamin D
(25OHD), stroke severity and functional status to changes in bone
remodelling in stroke patients.
Methods
Approval for the study was obtained from the Cambridge Local
Research Ethics Committee (Cambs LREC C, 2001). All the study
participants were admitted to an acute stroke unit with ﬁrst ever
stroke andwere taking part in the randomised placebo controlled trial
of 4 mg intravenous zoledronate vs. placebo to prevent bone loss in
hemiplegia. As part of that study protocol, all patients who were
randomised to either zoledronate or placebowere invited to volunteer
for a single trans-iliac bone biopsy. Patients received calcium (1 g) and
vitamin D (800 IU) daily during the trial. Full inclusion and exclusion
criteria for this trial have been published [1]. Additional exclusion
criteria for the biopsy study were disorders of blood coagulation,
warfarin therapy, respiratory disease and obesity. Patients had been
independent and ambulant before admissionwith a stroke and all had
hemiplegia affecting the lower limb. Theywere unable towalk 1 week
following stroke. All patients underwent measurement of bone
mineral density of both hips by DXA at study entry, repeated at
6 months. Two scales were used to evaluate patients' activity and
motor power at study entry and immediately prior to biopsy. These
were the Barthel Index (/100) [9] and the long term score (/48) of the
Scandinavian Stroke Scale [10].
Fifteen of the 31 trial subjects volunteered for a single trans-iliac
bone biopsy that was timed to occur approximately 10 weeks after the
stroke (mean 10.4+/−1.9 SD). In one subject, the biopsy specimenwas
incomplete leaving 14 samples for analysis. The reasons for not having
a biopsy were as follows: 9 patients declined, 5 were taking oral
warfarin therapy, and 2 had discontinued the study. The trans-iliac
bone biopsies were taken between January 2002 and October 2003
from 4 women (1 unsuitable for analysis) and 11 men, aged between
56 and 89 (mean 77.1+/−11) years. In order to explore the side-speciﬁc
effects of hemiplegia on bone turnover, it was decided at the start of
the study to sample alternately from the affected and unaffected side,
so 7 patients had a biopsy from the hemiplegic side and 7 from the
contra-lateral side. Upon unblinding, ﬁve patients had received
zoledronate and 9 had received placebo infusions. Biopsies were
obtained using a 7.5 mm internal diameter modiﬁed Bordier trephine
using local anaesthetic inﬁltration and intravenous sedation. In 11
patients it was possible to double demeclocycline labelling before the
biopsy (300 mg demeclocycline twice daily for 2 days, then a ten day
gap, followed by 300 mg twice daily for 2 days, followed by a biopsy
4 days after the last dose) [11]. Biopsies were cut in half longitudinally,
coded by the laboratory technician and all histomorphometric
measurements on blinded biopsies were made by the same observer
(KESP) with the exception of ES/BS (done by SV).
One half of the biopsy was embedded in methylmethacrylate for
histomorphometry (British Drug House Chemicals Ltd, Poole, Dorset),
the other was brieﬂy immersed in polyvinylalcohol (PVA) and chilled
in hexane for 10 min at −70 °C before mounting in PVA on a brass
chuck for TRAP staining and immunohistochemistry on cryosections
[12]. Undecalciﬁed cryosections (8 μm) were cut onto sectioning tape
using a Bright cryostat microtome (Huntingdon, UK) and reacted for
tartrate resistant acid phosphatase activity [13]. After air drying,
cryotape sections were placed in a freshly prepared buffered solution
of 18.75 mg of naphthol AS B1 phosphate, 93.75 mg of sodium tartrate
and 37 ml of 0.1 M tri sodium citrate (buffered to pH 4.5 with 2.1%
citric acid). They were then washed rapidly in a solution of 0.25 g of
sodium ﬂuoride in 250 ml distilled water before placing in a reagentconsisting of 18.75mg of fast garnet in 35ml of buffer (250ml distilled
water and 3.4 g sodium acetate buffered to pH 6.2 with acetic acid).
Tape sections were then washed in distilled water twice and cover
slipped with an aqueous mounting media.
After methylmethacrylate embedding, 8 μm undecalciﬁed sections
were cut with a Jung Polycut microtome (Leica, Milton Keynes, UK)
and stained with Von Kossa/Van Gieson stain for osteoid measure-
ment, trabecular surface and structural parameters and toluidine blue
stain for eroded surface and wall thickness (using polarised light)
before mounting on slides with DPX (Fisher Chemicals). Additional
15 μm sections were examined for ﬂuorescent labels using ultraviolet
light microscopy and a 365-nm ﬁlter. For all cancellous indices at least
two sections from levels separated by more than 150 μm (a reduced
thickness due to the limitations of using a half core biopsy) were
analysed from each biopsy to avoid replicate sampling of a single
surface event. Our detailed histomorphometric methods have been
published previously [14,15] but additions are described here. For the
present study, cancellous bone was deﬁned as the area bounded by,
parallel to and separated from the endocortical surface by 250 μm. The
remaining surface including the entire endosteum was analysed
separately. Osteoid thickness (O.Th) was measured at ×200magniﬁca-
tion, bone surface (BS) at ×80, wall thickness (W.Th) using polarised
light at ×125 and eroded surface (ES) at ×200. For O.Th, a minimum
number of 20 osteoid seams was analysed from each biopsy. All
osteoid widths greater than 3 μm were included in the analysis [16].
For W.Th a minimum of 25 bone remodelling units was measured for
each biopsy. Mineralising surface (MS/BS%) was deﬁned as the surface
extent of labelled (double-labelled+half single-labelled surface, dL+1/
2 sL) surface to cancellous bone surface. Mineral apposition rate
(distance between labels) in placebo patients included values of
0.3 μm/d for 2/7 biopsies that had single cortical labels only [17]. Bone
formation rate (BFR/BS um3/um2/d) was deﬁned as the amount of new
bonemineralised per day per unit of cancellous bone surface. Based on
the geometric probability density function, measures of mean
apparent widths were transformed into 3D mean apparent thick-
nesses by multiplying them by π/4 [18]. All histomorphometric
measurements are described using nomenclature approved by the
American Society for Bone and Mineral Research (ASBMR [19]), with
the exception of ‘cortical osteoid area’, Ct. OAr/BAr.
Endocortical histomorphometry
The endocortical surfaces were deﬁned for the purposes of this
study as both inner bone surfaces and cancellous surfaces up to
250 μm into the medullary cavity measuring parallel to the plane of
the inner surfaces. Osteoid surface (Ec. OS/BS) was measured on these
surfaces in the same manner as the cancellous OS/BS.
Cortical histomorphometry
Mean cortical thickness (Ct. Th) was measured automatically after
drawing periosteal and endocortical surfaces from three sections and
using correction for section obliquity. Cortical osteoid area (Ct. OAr/
BAr) and cortical porosity (%) were measured as follows. The entire
Von Kossa stained cortex was captured at 100× magniﬁcation (2
cortices per biopsy) using automated montaging software and a
digital camera. Canals were deﬁned on the cortex image using a digital
drawing pen and osteoid was ﬁlled in. The osteoid area was measured
directly using ImageJ software (ImageJ 1.32e, NIH, USA available to
download at http://rsb.info.nih.gov/ij/) and osteoid area as a percen-
tage of cortical bone area was calculated. Assumptions of isotropy
used to convert 2D to 3D values in cancellous bone are not met in
cortical bone [19,20], so mean cortical areas in 2D cannot be
extrapolated to mean volumes in 3D. Therefore, Ct. OAr/BAr is
reported, acknowledging that the correct ASBMR nomenclature is to
use either 2D or 3D referents only in a single publication.
Table 2
Basic static, endocortical and dynamic histomorphometry in stroke patients [median
(IQR)]
Measurement n Zoledronate 4 mg n Placebo p Valuea
Static parameters
BV/TV (%) 5 21.4 (14.0, 25.6) 9 18.2 (16.6, 21.9) 0.894
OS/BS (%) 5 8.06 (4.73, 1.53) 9 2.26 (1.59, 4.91) 0.033
OV/BV (%) 5 0.89 (0.48, 1.46) 9 0.23 (0.18, 0.45) 0.046
O.Th (um) 5 6.35 (6.01, 7.68) 9 6.83 (5.00, 7.35) 0.689
ES/BS (%) 5 4.98 (3.67, 7.46) 9 5.76 (4.89, 6.54) 0.594
W.Th (um) 5 32.5 (28.4, 35.4) 9 28.3 (24.4, 29.1) 0.046
Frozen sections
TRAP+ cells (/mm2) 5 0.05 (0.01, 0.17) 9 0.35 (0.11, 0.52) 0.023
Endocortical parameters
Ec. OS/BS (%) 5 14.0 (9.0, 18.8) 9 3.8 (2.7, 7.5) 0.011
Ct. OAr/BAr (%) 5 0.43 (0.10, 0.58) 9 0.11 (0.06, 020) 0.110
Ct. Porosity (%) 5 5.84 (3.60, 7.38) 9 5.07 (2.93, 8.16) 0.790
Ct. Th (um) 5 708 (523, 875) 9 777 (559, 1166) 0..351
Dynamic parameters
MS/BS (%) 4 1.80 (0.29, 2.62)b 7 1.25 (0.00, 2.86)c 0.924
MAR (um/d) 4 0.51 (0.11, 0.91)b 7 0.55 (0.30, 0.86)d 0.925
BFR/BS (um3/um2/d) 4 0.01 (0.001, 0.03)b 7 0.01 (0.00, 0.03)c 0.924
a Wilcoxon Ranks Sums test.
b Includes zero value from 1 zoledronate patient with no labels present.
c Includes zero values from 2 placebo patients with only single cortical labels.
d Assumed MAR of 0.3 um/d in 2 placebo patients with only single cortical labels
(Foldes method).
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Mean histomorphometric parameters from the stroke patients
were compared withmean values from the UK healthy adult reference
range of Vedi et al [14].
Statistical analysis
Data were analysed using the JMP statistical package JMP (v 4.0,
SAS institute, Cary, NC, USA). Signiﬁcance was determined by
Student's t-test and either a 2-sample t-test or Dunnett's test when
comparing stroke patients with reference data. For non-normally
distributed data, signiﬁcance was determined by use of the Wilcoxon/
Kruskals–Wallis 2 sample test. To calculate the individual short term
precision of the measurements, ﬁve repeated measurements were
made on 1 day. Each measurement was taken from the same section.
Intra-observation (precision) was as follows: BV/TV 1.9%, OS/BS 4.2%,
O.Th 2.4%, and W.Th 3.1%. Since the reference histomorphometry data
were generated locally, coefﬁcients of inter-observer variation were
calculated after both observers (KESP and SV) recorded three
measurements for each parameter after examining 2–3 sections
from the same test biopsy. The inter-observer coefﬁcients of variation
were BV/TV 9.1%, OS/BS 11.3%, O.Th 8.8%, and W.Th 8.2%.
Results
Patient demographics are shown in Table 1. Static histomorpho-
metry could be performed in 5 zoledronate patients and 9 placebo
patients. The groups were comparable in terms of age and severity of
stroke (as assessed by the Scandinavian Stroke Scale, SSS and Barthel
Index, BI) at the time of biopsy. Qualitative assessment of the stroke
biopsies showed no evidence of woven bone, marrow ﬁbrosis or signs
of cellular toxicity. The sample sizes for comparison were very small
(n=7 per group), but there were no differences between the iliac
biopsies from the hemiplegic side and unaffected side for any
parameter (0.90Np(all)N0.13). However, in the placebo group there
was a markedly greater loss of total hip BMD on the hemiplegic side
compared to the unaffected side in the 6 months following stroke
(Table 1). Leg power impairment at 3 months after stroke (b5 on the
SSS) was not associated with statistically signiﬁcant differences in any
parameter (0.8Np(all)N0.13).
The ES/BS was not signiﬁcantly different between groups, but the
zoledronate treated group had fewer TRAP+ cells per mm2 than
placebo. The OS/BS was signiﬁcantly higher in zoledronate-treated
patients than placebo-treated patients (Table 2). The zoledronate-
treated stroke patients also had signiﬁcantly higher endocorticalTable 1
Demographics in stroke patients [mean (95% CI)]
Measurement Zoledronate 4 mg Placebo p
Valuea
Demographics
Age 67.2 (52.8, 81.6) 72.7 (64.3, 81.0)
n (female, male) (affected,
unaffected)
5 (1, 4) (2, 3) 9 (2, 7) (5, 4)
Interval (weeks) from stroke to
biopsy
9.3 (7.5, 11.1) 10.8 (9.4, 12.1)
Interval (weeks) from zol to biopsy 5.6 (4.2, 7.1)
SSS/48 29 (21, 37) 28 (22, 39)
SSS Leg Power/5 4.2 (2.6, 5.8) 3.6 (2.2, 5.0)
Barthel Index/100 58 (40, 76) 57 (34, 80)
25OHD (mmol/l) 41.4 (20.5, 62.7) 42.9 (29.5, 56.7)
DXA results
Baseline total hip BMD (g/cm2) 1.08 (0.93, 1.22) 0.98 (0.87, 1.09)
ΔTotal hip BMDb hemiplegic side (%) +1.4 (−0.2, +3.0) −3.3 (−6.4, −0.2) 0.013
Δ Total hip BMDb unaffected side (%) +1.9 (−2.0, +5.7) −0.5 (−2.7, +1.7) 0.160
a Student's t-test.
b Change in BMD over 6 months.OS/BS (but not cortical OAr/BAr) than placebo-treated patients, with
no difference in cortical porosity or thickness.
Of the 11 demeclocycline labelled patients, 4 were from the
zoledronate group and 7 from the placebo group. Among the 7 placebo
group biopsies, 2 samples displayed single cortical labelling only (with
no double labels in cancellous or cortical bone). In those 2 samples, the
MAR was assumed to be 0.3 μm/d [17]. Double labelling was seen in
three biopsies from zoledronate treated patients, but in one biopsy
there were no labels in any compartment (Table 2). There was no
signiﬁcant difference in MS/BS or BFR/BS between zoledronate-
treated and placebo-treated stroke patients. However, values for
these indices in both groups were substantially lower than in the
healthy controls (Table 3). MAR was also similar in the two patient
groups and similar to that seen in healthy controls.
Discussion
In iliac bone biopsies obtained within 3 months after acute stroke,
bone formation at the tissue level was reduced when compared to
healthy controls, irrespective of whether patients were receiving
zoledronate therapy or placebo. However, the number of osteoclastic
cells was lower in patients treated with zoledronate than withTable 3
Histomorphometric parameters in stroke patients vs. healthy controls [mean (SD)]
Measurement n All Stroke Pts n Controls p Value
Age range 56–89 51–80
Sex 3f, 11m 16f, 12m
BV/TV (%) 14 19.6 (4.6) 28 22.3 (4.3) 0.065
O.Th (um) 14 6.5 (1.1) 28 6.1 (2.1) 0.537
ES/BS (%) 14 5.7 (1.7) 28 1.6 (0.7) b0.0001a
MS/BS (%) 11 1.6 (1.3)c 28 11.1 (5.5) b0.0001a
MAR (um/d) 11 0.6 (0.3)d 28 0.6 (0.1) 0.454
Zol Pla
OS/BS (%) 5 9 7.7 (3.9) 3.0 (1.7) 28 27.8 (11.8) b0.05b
OV/BV (%) 5 9 1.0 (0.6) 0.3 (0.2) 28 4.0 (2.2) b0.05b
W.Th (um) 5 9 32.0 (4.0) 28.3 (3.4) 28 34.9 (3.0) b0.05b
a Signiﬁcantly different from control mean by 2 sided t-test.
b Signiﬁcantly different from control mean by Dunnett's test.
c Includes zero values from 1 zoledronate patient (no labels present) and from 2
placebo patients (single cortical labels).
d Includes assumed MAR of 0.3 um/d in 2 placebo patients with only single cortical
labels (Foldes method).
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zoledronate. The increase in eroded surface in both zoledronate and
placebo treated patients when compared to controls may thus reﬂect
reduced bone formation rather than increased resorption, resulting in
the failure of bone formation to occur within previously formed
resorption cavities. The reason for the higher osteoid surface in
zoledronate-treated patients than in those receiving placebo is
unclear since the mineralising surface was similar in the two groups.
The apparent difference in osteoid surface may reﬂect the large
variance in the small number of samples measured or multiple testing
of signiﬁcance. The lack of demeclocyline label in one zoledronate-
treated patient was noted; potential explanations for this include
failure to absorb or take demeclocycline (for any reason), suppression
of bone remodelling by zoledronate and absent labelling as occasion-
ally observed in normal subjects.
The ﬁnding of reduced tissue level bone formation early after
stroke is in agreement with studies demonstrating that biochemical
markers of bone formation were reduced (when compared to
controls) in the early phase of stroke recovery [2] and throughout
the ﬁrst year [3] in addition to a marked early increase in resorption
markers. We did not measure turnover markers in the present study
and bone histomorphometric data have not been previously reported
in the stroke population. Because the biopsies were obtained within
3 months of stroke, it is assumed that bone formation measures
reported here predominately reﬂect the activity within cancellous
Basic Multicellular Units (BMUs) that were initiated prior to stroke,
with fewermeasurements from BMUs initiated after stroke. Since pre-
stroke biopsies were not available, indices of bone formation prior to
stroke are unknown. Nevertheless, the markedly lower mineralising
surfaces in the stroke patients, irrespective of treatment, when
compared to healthy controls support the contention that tissue
level formation is signiﬁcantly suppressed early after stroke, whether
in new or previously initiated BMUs. Our results suggest that one
explanation for bone loss in stroke may be an increase in the
remodelling space through failure of the coupled formation that
would normally accompany bone resorption. There may be local or
systemic factors that are responsible for this altered dynamic; for
instance, reversal may be prolonged or osteoblast recruitment and/or
activity may be impaired.
Histomorphometric assessment of biopsies obtained in the pivotal
Phase III zoledronate study (HORIZON) demonstrated the expected
reduction in remodelling rate but also suggested that osteoblastic
activity, as assessed by mineral apposition rate, was increased by
zoledronate relative to placebo [21]. HORIZON also showed preserva-
tion of cancellous bone microarchitecture in zoledronate-treated
patients, consistent with an anti-resorptive effect, although no
increase in the degree of matrix mineralisation was demonstrated.
In the present study no signiﬁcant difference in mineral apposition
rate was seen between zoledronate and placebo-treated patients,
perhaps due to the small sample available here [21].
In the present study, there were no differences in indices of bone
remodelling between the hemiplegic and unaffected sides (although
the sample size was very small for this comparison), in contrast to the
marked DXA BMD changes at the hemiplegic and unaffected hips
observed in the patients (Table 1). Using DXA, hemiplegia has been
shown to have both generalised and localised effects on the skeleton
[22–24]. Iliac bone remodellingmay therefore be representative of the
generalised (or indirect) skeletal effects of stroke, rather than those
directly due to altered mechanical loading or muscle forces. It has
been suggested that such generalised bone loss after stroke occurs
because of changes in calciotropic hormone secretion such as raised
ionised calcium inhibiting parathyroid hormone [25].
Themain limitation of the present study is themodest sample size,
particularly for comparison of demeclocycline-derived indices. The
large measurement and sampling variance associated with bone
histomorphometry means that with the numbers included in ourstudy, only large differences between zoledronate and placebo-
treated patients could reliably be demonstrated. The lack of a
contemporaneous control group for comparison is a shortcoming
common to most histomorphometry studies, but this is mitigated by
the similarities between our ﬁndings and those of Recker et al [21].
The control data in this study were derived from healthy subjects and
were obtained by ourselves using similar methods. Finally, since the
biopsies were obtained relatively early after stroke, the long-term
steady state effects of stroke and of zoledronate could not be
determined in this study.
In conclusion, our results indicate reduced tissue level bone
formation in iliac bone early after stroke with a reduction in
osteoclastic cells only in zoledronate-treated patients. Further studies
are required to elucidate further the effects of acute stroke on bone
remodelling and the mechanisms by which bisphosphonates inﬂu-
ence both bone resorption and formation in stroke patients.
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